drugset / Trial / NCT01944319
Meropenem Dosage Strategy Based on PPK Model
RandomizedParallel-groupOpen-labelTreatment
Summary
To evaluate the clinical and economical benefits of a meropenem dosage strategy based on a population pharmacokinetic(PPK)-pharmacodynamic(PD) model in lower respiratory tract infection patients.
Timeline
- Start
- 2013-07
- Primary completion
- 2015-10
- Completion
- 2015-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Meropenem | Small molecule | 1.5 g | — |
| Subject | Meropenem | Small molecule | 2 g | — |